Minaris Advanced Testing spotlighted the Test Article Receipt (T.A.R.) team in Behind the Scenes to discuss sample management and testing processes.
Published
Signal category
Operations & Supply
Quote
“In this episode of our Behind the Scenes series, we spotlight our Test Article Receipt (T.A.R.) team, a key early step in the sample management process at Minaris Advanced Testing.”
— Minaris team
Company
Minaris
Advancing Therapies Forward
- Industry
- Pharmaceutical Manufacturing
- Location
- Philadelphia, US
- Company size
- 794 employees
Minaris is a global cell and gene therapy (CGT) CDMO and a multimodality biosafety testing provider. With more than 25 years of CGT development and manufacturing expertise and more than 40 years in biosafety testing, Minaris combines deep legacy experience with state-of-the-art GMP facilities, and is a fully US-owned organization under new ownership and management, built for today’s evolving therapeutic landscape. Our CDMO team supports CGT innovators from IND through commercial supply, and our testing business delivers GMP analytics, biosafety, viral clearance, and product characterization across CGT and biologics. With 5 global sites on 3 continents, we operate with one mission—to support clinical and commercial therapeutic programs hand in hand with our partners to get more therapies to more patients. We are united by our commitment to excellence, reliability, and a patient-focused purpose as we enable innovators to deliver new therapies and expand patient access worldwide. For more information, visit https://minaris.com. Minaris Advanced Therapies is wholly owned by Altaris, LLC.